BioXcel Therapeutics (BTAI) Receivables - Net (2019 - 2026)

BioXcel Therapeutics (BTAI) posted quarterly Receivables - Net of $216000.0 for Q1 2026, down 7.3% quarter-over-quarter from $233000.0 in Q4 2025.

BioXcel Therapeutics (BTAI) Receivables - Net (2019 - 2026) Analysis & Trends

BioXcel Therapeutics' Receivables - Net history runs 6 years deep, the most recent figure standing at $216000.0 for Q1 2026.

In Q1 2026, Receivables - Net changed N/A year-over-year to $216000.0; the TTM figure through Mar 2026 stood at $216000.0 (changed N/A YoY), while the FY2025 annual figure was $233000.0, up 77.86% from the prior year.
Receivables - Net for Q1 2026 stood at $216000.0, down from $233000.0 in the prior quarter.
The five-year high for Receivables - Net was $812000.0 in Q2 2024, with the low at $3000.0 in Q3 2024.
The 5-year median for Receivables - Net is $240500.0 (2022), against an average of $296500.0.
Peak annual rise in Receivables - Net reached 88.4% in 2024, while the deepest fall reached 99.59% in 2024.
BioXcel Therapeutics' Receivables - Net stood at $248000.0 in 2022, then sank by 71.37% to $71000.0 in 2023, then surged by 84.51% to $131000.0 in 2024, then jumped by 77.86% to $233000.0 in 2025, then declined by 7.3% to $216000.0 in 2026.
Business Quant data shows BTAI's Receivables - Net at $216000.0 in Q1 2026, $233000.0 in Q4 2025, and $17000.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	44.40 Bn	43.44 Bn	-
2	Teva Pharmaceutical Industries	43.68 Bn	40.02 Bn	2.15 Bn
3	Zoetis	32.31 Bn	30.63 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.60 Bn	22.80 Bn	5.10 Bn
5	United Therapeutics	21.98 Bn	19.32 Bn	683.80 Mn
6	Viatris	18.87 Bn	17.98 Bn	1.46 Bn
7	Neurocrine Biosciences	15.58 Bn	15.19 Bn	935.80 Mn
8	Elanco Animal Health	11.97 Bn	11.44 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.13 Bn	9.97 Bn	-
10	BioXcel Therapeutics	24.94 Mn	24.94 Mn	160,000.00

Download Data